HIV-1 Antigen and HIV-1/HIV-2 A reliable solution for the quality detection of antibodies
Elecsys® HIV Tags PT, human ⁇ ⁇ and plasma examples HIV‑1 p24 The antigen with HIV‑1 (group M and O) and HIV‑2“Anticorps” in vitro an improved determination for qualitative determination immunoassay test. Test, HIV‑1 and/or HIV‑2 infection in diagnosis, especially acute or primary HIV‑1 infections is used as a helper to recognize. In addition 2 older individuals and pregnant women HIV It also provides support to detect infection.
Extensive Diagnostic Ability
Elecsys® HIV Tags PT, both HIV‑1 p24 The antigen both HIV‑1 and HIV‑2Based on ́s Total antibodies It provides the possibility of high accuracy diagnosis in the early and late stages of infection. This combination, test primary infection Provides reliable results even during periods.
Compatible Devices
- cobas e 602
- cobas e 411
- cobas e 601
Working in full compliance with these devices Elecsys® HIV Tags PT, electrochemia immunophoassay (ECLIA) works with technology. Thanks to this technology High sensitivity, repeatability and automation advantage obtained.
Clinical Use Purpose
Elecsys® HIV Tags PTIt is effective in early diagnosis of infection, especially:
- Acute HIV-1 infections,
- HIV-1 group O variants,
- HIV-2 infections
Difficulty in high cases detailed scan provides. If the test results are positive, HIV‑1 p24 The antigen, HIV‑1 Anticorps, HIV‑2 Anticorps ⁇ HIV‑1 The group is an anti- there is no distinction.
Quality Control and Reliability
PreciControl HIV Home II and PreciControl HIV; HIV‑2+GrpOusing this test cobas e 602 analysis quality control processes supports. In this way, laboratories comply with standards, reliable results We can offer.
Important Notes
- Test only in vitro diagnostic purposes intended for use.
- Scan of blood or plasma donors is not used for the purpose.
Elecsys® HIV Tags PTEarly diagnosis, comprehensive scanning and high reliability HIV strengthens diagnostic approach to infections is an advanced technology solution. RocheIt is possible to increase clinical assurance and maintain public health with this test developed by .
